Share chart Trevi Therapeutics, Inc.
Extended chart
Simple chart
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., биофармацевтическая компания, работающая на клинической стадии, специализируется на разработке и коммерциализации Haduvio для лечения серьезных состояний кашля, воздействующих на центральную и периферическую нервную системы. Компания разрабатывает Haduvio, пероральную форму налбуфина с пролонгированным высвобождением, которая проходит фазу 2b/3 клинических испытаний для лечения хронического зуда и хронического кашля у пациентов с идиопатическим легочным фиброзом. Компания имеет лицензионное соглашение с Endo Pharmaceuticals Inc. more details| IPO date | 2019-05-07 |
|---|---|
| ISIN | US89532M1018 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.trevitherapeutics.com |
| Цена ао | 6.46 |
| Change price per day: | 0% (6.19) |
|---|---|
| Change price per week: | -6.21% (6.6) |
| Change price per month: | -0.1613% (6.2) |
| Change price per 3 month: | +54.36% (4.01) |
| Change price per half year: | +125.09% (2.75) |
| Change price per year: | +117.96% (2.84) |
| Change price per 3 year: | +180.09% (2.21) |
| Change price per 5 year: | +125.91% (2.74) |
| Change price per year to date: | +50.98% (4.1) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| NEA Management Company, LLC | 11370376 | 18.93 |
| Frazier Life Sciences Management, L.P. | 6663590 | 11.09 |
| Fairmount Funds Management LLC | 5696515 | 9.48 |
| Rubric Capital Management LP | 5684420 | 9.46 |
| Viking Global Investors, L.P. | 4400000 | 7.32 |
| VR Adviser, LLC | 3050022 | 5.08 |
| MAI Capital Management | 1534652 | 2.55 |
| Vanguard Group Inc | 1499751 | 2.5 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 885924 | 1.47 |
| Opaleye Management Inc. | 835800 | 1.39 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Ms. Jennifer L. Good | Co-Founder, CEO, President & Director | 781.85k | 1965 (60 years) |
| Dr. Thomas R. Sciascia M.D. | Co-Founder & Chief Scientific Officer | 530.48k | 1953 (72 years) |
| Ms. Lisa Delfini | Chief Financial Officer | N/A | 1970 (55 years) |
| Mr. Christopher Galletta | Controller & Chief Accounting Officer | N/A | 1978 (47 years) |
| Katie McManus | Communications Manager | N/A | |
| Mr. Farrell Simon Pharm.D. | Chief Commercial Officer | N/A | |
| Ms. Danine Summers | Vice President of Medical Affairs | N/A | 1958 (67 years) |
Address: United States, New Haven. CT, 195 Church Street - open in Google maps, open in Yandex maps
Website: https://www.trevitherapeutics.com
Website: https://www.trevitherapeutics.com
